AXSOME THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+65.0% +$77M
$196M
Cost of Revenue↑+17.3% +$2M
$12M
R&D↓-11.3% -$6M
$49M
SG&A↑+49.5% +$56M
$169M
D&A↓-11.6% -$15K
$114K
Operating Income↑+26.4% +$17M
$-46M
EBITDA↓-11.6% -$15K
$114K
Interest Expense↑+40.4% +$2M
$-3M
Interest Income↓-36.7% -$1M
$2M
Other Income/Expense↑+40.4% +$5M
$-7M
Pretax Income↑+26.9% +$17M
$-47M
Tax Provision
$0
Net Income↑+26.9% +$17M
$-47M
Operating Margin↑+32.8pts
-27.0%
Net Margin↑+34.0pts
-27.6%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)↑+0.3pts
0.3%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-4.3pts
-2.1%
ETR Foreign Differential (pp)
-6.3%
Operating Lease Cost↑+116.7% +$679K
$1M
Revenue YoY Variation↓-1.0pts
65.0%
Income YoY Variation↑+27.2pts
26.4%
Revenue QoQ Variation↑+1.3pts
14.6%
Income QoQ Variation↓-45.3pts
-25.6%